TREAT or not to treat: Anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4;TREAT or not to treat : Anémie du patient diabétique de type 2 aux stades 3 et 4 de la maladie rénale chronique

Nephrologie et Therapeutique

Volumn 7, Issue 1, 2011, Pages 2-9

  Choukroun, Gabriel ^a   Renou, Marianne ^a   Lecaque, Caroline ^a   Jauréguy, Maïté ^a  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Anemia; Cancer; Cardiovascular events; Chronic kidney disease; Darbepoetin alfa; Erythropoiesis stimulating agents; Quality of life; Type 2 diabetes

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TREATMENT OUTCOME;

EID: 79751536035     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2010.11.003     Document Type: Short Survey

References (33)

1. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, and J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial N Engl J Med 316 1987 73 78 (Pubitemid 17052741)
2. J.W. Eschbach, M.H. Abdulhadi, J.K. Browne, B.G. Delano, M.R. Downing, and J.C. Egrie Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial Ann Intern Med 111 1989 992 1000 (Pubitemid 20034923)
3. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, and D.M. Okamoto The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590 (Pubitemid 28385655)
4. R.D. Kilpatrick, C.W. Critchlow, S. Fishbane, A. Besarab, C. Stehman-Breen, and M. Krishnan Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients Clin J Am Soc Nephrol 3 2008 1077 1083
5. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, and M. Wolfson Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
6. T.B. Drüeke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, and D. Tsakiris Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
7. S.D. Roger, L.P. McMahon, A. Clarkson, A. Disney, D. Harris, and C. Hawley Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial J Am Soc Nephrol 15 2004 148 156 (Pubitemid 38020706)
8. A. Levin, O. Djurdjev, C. Thompson, B. Barrett, J. Ethier, and E. Carlisle Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD Am J Kidney Dis 46 2005 799 811 (Pubitemid 41505453)
9. E. Ritz, M. Laville, R.W. Bilous, D. O'Donoghue, A. Scherhag, and U. Burger Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACORD) study Am J Kidney Dis 49 2007 194 207 (Pubitemid 46178405)
10. J. Rossert, A. Levin, S.D. Roger, W.H. Hörl, B. Fouqueray, and C. Gassmann-Mayer Effect of early correction of anemia on the progression of CKD Am J Kidney Dis 47 5 2006 738 750
11. I.C. Macdougall, R.M. Temple, and J.T. Kwan Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open label, prospective, randomized, comparative group trial Nephrol Dial Transplant 21 2006 1 10
12. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. De Zeeuw, and K.U. Eckardt A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
13. P.A. Marsden Treatment of anemia in chronic kidney disease - Strategies based on evidence N Engl J Med 361 2009 2089 2090
14. L. Szczech Anemia trials: lessons for clinicians, politicians, and third-party payers Kidney Int 77 2010 479 480
15. L.A. Szczech, H.X. Barnhart, S. Sapp, G.M. Felker, A. Hernandez, and D. Reddan A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment Kidney Int 77 2010 239 246
16. S. Fishbane, and N. Miyawaki Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Kidney Int 77 2010 175 177
17. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis- stimulating agents-time for a reevaluation N Engl J Med 362 2010 189 192
18. R.N. Foley, P.S. Parfrey, J.D. Harnett, G.M. Kent, D.C. Murray, and P.E. Barre The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am J Kidney Dis 28 1996 53 61 (Pubitemid 26231466)
19. P.C. Tong, A.P. Kong, W.Y. So, M.H. Ng, X. Yang, and M.C. Ng Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes Diabetes Care 29 2006 2439 2444 (Pubitemid 44912249)
20. K. Rossing, P.K. Christensen, P. Hovind, L. Tarnow, P. Rossing, and H.H. Parving Progression of nephropathy in type 2 diabetic patients Kidney Int 66 2004 1596 1605 (Pubitemid 39298395)
21. H. Ueda, E. Ishimura, T. Shoji, M. Emoto, T. Morioka, and N. Matsumoto Factors affecting progression of renal failure in patients with type 2 diabetes Diabetes Care 26 2003 1530 1534 (Pubitemid 36929191)
22. W.F. Keane, B.M. Brenner, D. De Zeeuw, J.P. Grünfeld, and J. McGill The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study Kidney Int 63 2003 1499 1507 (Pubitemid 36350016)
23. T.C. Mix, R.M. Brenner, M.E. Cooper, D. De Zeeuw, P. Ivanovich, and A.S. Levey Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease Am Heart J 149 2005 408 413 [Erratum in: Am Heart J 2005;150-153] (Pubitemid 40585402)
24. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. De Zeeuw, and K.U. Eckardt Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Am J Kidney Dis 54 2009 59 69
25. M. Henke, R. Laszig, C. Rübe, U. Schäfer, K.D. Haase, and B. Schilcher Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260 (Pubitemid 37324251)
26. B. Leyland-Jones, V. Semiglazov, M. Pawlicki, T. Pienkowski, S. Tjulandin, and G. Manikhas Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J Clin Oncol 23 2005 5960 5972
27. F. Locatelli, L. Del Vecchio, and P. Pozzoni Anemia and cardiovascular risk: the lesson of the CREATE Trial J Am Soc Nephrol 17 2006 S262 S266
28. G.F. Strippoli, S. Tognoni, S.D. Navaneethan, A. Nicolucci, and J.C. Craig Haemoglobin targets: we were wrong, time to move on Lancet 369 2007 346 350 (Pubitemid 46188478)
29. Villar E, Livre M, Kessler M, Lemaître V, Alamartine E, Rodier M, et al. Anaemia normalization in patients with type 2 diabetes and chronic kidney disease; Results of the NEPHRODIAB2 randomized trial. Soumis.
30. L.A. Szczech, H.X. Barnhart, J.K. Inrig, D.N. Reddan, S. Sapp, and R.M. Califf Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes Kidney Int 74 2008 791 798
31. S.D. Solomon, H. Uno, E.F. Lewis, K.U. Eckardt, J. Lin, and E.A. Burdmann Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
32. A.K. Singh The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis Clin J Am Soc Nephrol 5 2010 553 556
33. ® Therapy (TREAT) Study Nephrol Dial Transplant 25 2010 2846 2850